Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Revolution Medicines, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

REDWOOD CITY, CALIF., MARCH 17, 2026 (GLOBE NEWSWIRE) -- REVOLUTION MEDICINES, INC. (NASDAQ:RVMD), A LATE-STAGE CLINICAL ONCOLOGY COMPANY DEVELOPING TARGETED THERAPIES FOR PATIENTS WITH RAS-ADDICTED CANCERS, TODAY ANNOUNCED THAT NINE ORAL AND POSTER PRESENTATIONS HIGHLIGHTING ADVANCES ACROSS ITS RAS(ON) INHIBITOR PIPELINE WILL BE FEATURED AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING, TAKING PLACE APRIL 1722, 2026 IN SAN DIEGO.

REVOLUTION MEDICINES TO SHOWCASE PROGRESS ACROSS RAS(ON) TARGETED ONCOLOGY PIPELINE WITH MULTIPLE PRESENTATIONS AT THE 2026 AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING

REDWOOD CITY, CALIF., FEB. 25, 2026 (GLOBE NEWSWIRE) -- REVOLUTION MEDICINES, INC. (NASDAQ: RVMD), A LATE-STAGE CLINICAL ONCOLOGY COMPANY DEVELOPING TARGETED THERAPIES FOR PATIENTS WITH RAS-ADDICTED CANCERS, TODAY ANNOUNCED ITS FINANCIAL RESULTS FOR THE QUARTER AND FULL YEAR ENDED DECEMBER 31, 2025, AND PROVIDED AN UPDATE ON CORPORATE PROGRESS.

REVOLUTION MEDICINES REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND UPDATE ON CORPORATE PROGRESS

REDWOOD CITY, CALIF., FEB. 24, 2026 (GLOBE NEWSWIRE) -- REVOLUTION MEDICINES, INC. (NASDAQ: RVMD), A LATE-STAGE CLINICAL ONCOLOGY COMPANY DEVELOPING TARGETED THERAPIES FOR PATIENTS WITH RAS-ADDICTED CANCERS, TODAY ANNOUNCED THAT MARK A. GOLDSMITH, M.D., PH.D., THE COMPANY'S CHIEF EXECUTIVE OFFICER AND CHAIRMAN, WILL PARTICIPATE IN A FIRESIDE CHAT AS PART OF THE TDCOWEN46TH ANNUAL HEALTH CARE CONFERENCE ON TUESDAY, MARCH 3 AT 9:50 A.M. ET.

REVOLUTION MEDICINES TO PARTICIPATE IN TDCOWEN46TH ANNUAL HEALTH CARE CONFERENCE

REDWOOD CITY, CALIF., FEB. 18, 2026 (GLOBE NEWSWIRE) -- REVOLUTION MEDICINES, INC. (NASDAQ: RVMD), A LATE-STAGE CLINICAL ONCOLOGY COMPANY DEVELOPING TARGETED THERAPIES FOR PATIENTS WITH RAS-ADDICTED CANCERS, TODAY ANNOUNCED THAT IT WILL REPORT FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2025 ON WEDNESDAY, FEBRUARY 25, 2026, AFTER MARKET CLOSE. AT 4:30 P.M. ET THAT DAY (1:30 P.M. PT), MEMBERS OF REVOLUTION MEDICINES' SENIOR MANAGEMENT TEAM WILL HOST A WEBCAST TO DISCUSS THE FINANCIAL RESULTS FOR THE QUARTER AND FULL YEAR, AND PROVIDE AN UPDATE ON CORPORATE PROGRESS.

REVOLUTION MEDICINES TO REPORT FINANCIAL RESULTS FOR FOURTH QUARTER AND FULL YEAR 2025 AFTER MARKET CLOSE ON FEBRUARY 25, 2026

REDWOOD CITY, CALIF., FEB. 04, 2026 (GLOBE NEWSWIRE) -- REVOLUTION MEDICINES, INC. (NASDAQ: RVMD), A LATE-STAGE CLINICAL ONCOLOGY COMPANY DEVELOPING TARGETED THERAPIES FOR PATIENTS WITH RAS-ADDICTED CANCERS, TODAY ANNOUNCED THAT MARK A.

REVOLUTION MEDICINES TO PARTICIPATE IN GUGGENHEIM SECURITIES EMERGING OUTLOOK: BIOTECH SUMMIT 2026

BREAKTHROUGH THERAPY DESIGNATION GRANTED TO ZOLDONRASIB FOR THE TREATMENT OF ADULT PATIENTS WITH KRAS G12D-MUTATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE BEEN PREVIOUSLY TREATED WITH ANTI-PD-1/PD-L1 THERAPY AND PLATINUM-BASED CHEMOTHERAPY FIRST BREAKTHROUGH THERAPY DESIGNATION FOR AN INVESTIGATIONAL DRUG SPECIFICALLY TARGETING KRAS G12D MUTATION IN NSCLC REVOLUTION MEDICINES' THIRD RAS(ON) INHIBITOR TO RECEIVE THIS DESIGNATION REDWOOD CITY, CALIF., JAN. 08, 2026 (GLOBE NEWSWIRE) -- REVOLUTION MEDICINES, INC. (NASDAQ: RVMD), A LATE-STAGE CLINICAL ONCOLOGY COMPANY DEVELOPING TARGETED THERAPIES FOR PATIENTS WITH RAS-ADDICTED CANCERS, TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS GRANTED BREAKTHROUGH THERAPY DESIGNATION TO ZOLDONRASIB, A RAS(ON) G12D-SELECTIVE INHIBITOR, FOR THE TREATMENT OF ADULT PATIENTS WITH KRAS G12D-MUTATED LOCALLY ADVANCED OR METASTATIC NSCLC WHO HAVE BEEN PREVIOUSLY TREATED WITH ANTI-PD-1/PD-L1 THERAPY AND PLATINUM-BASED CHEMOTHERAPY.

REVOLUTION MEDICINES ANNOUNCES FDA BREAKTHROUGH THERAPY DESIGNATION FOR ZOLDONRASIB

REDWOOD CITY, CALIF., JAN. 05, 2026 (GLOBE NEWSWIRE) -- REVOLUTION MEDICINES, INC. (NASDAQ: RVMD), A LATE-STAGE CLINICAL ONCOLOGY COMPANY DEVELOPING TARGETED THERAPIES FOR PATIENTS WITH RAS-ADDICTED CANCERS, TODAY ANNOUNCED THAT MARK A. GOLDSMITH, M.D., PH.D., THE COMPANY'S CHIEF EXECUTIVE OFFICER AND CHAIRMAN, WILL DELIVER A CORPORATE PRESENTATION AS PART OF THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE ON MONDAY, JANUARY 12, 2026 AT 10:30 A.M. PT.

REVOLUTION MEDICINES TO PRESENT AT 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

COMPANY IS WINDING DOWN GLOBAL ENROLLMENT FOR THE RASOLUTE 302 CLINICAL TRIAL STUDYING DARAXONRASIB IN PATIENTS WITH PREVIOUSLY TREATED PDAC AND REMAINS ON TRACK FOR DATA READOUT IN 2026 COMPANY HAS INITIATED RASOLUTE 304, A PHASE 3 CLINICAL TRIAL OF DARAXONRASIB AS ADJUVANT TREATMENT FOR PATIENTS WITH RESECTABLE PDAC, AND REMAINS ON TRACK TO INITIATE RASOLUTE 303 FOR PATIENTS WITH FIRST LINE METASTATIC PDAC THIS YEAR DARAXONRASIB HAS RECEIVED FDA BREAKTHROUGH THERAPY DESIGNATION, ORPHAN DRUG DESIGNATION AND A COMMISSIONER'S NATIONAL PRIORITY VOUCHER NEW LEADERSHIP APPOINTMENTS STRENGTHENED GLOBAL DEVELOPMENT AND COMMERCIALIZATION CAPABILITIES REVOLUTION MEDICINES TO HOLD WEBCAST TODAY AT 4:30 P.M. EASTERN TIME REDWOOD CITY, CALIF.

REVOLUTION MEDICINES REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND UPDATE ON CORPORATE PROGRESS

REDWOOD CITY, CALIF., NOV. 04, 2025 (GLOBE NEWSWIRE) -- REVOLUTION MEDICINES, INC. (NASDAQ: RVMD), A LATE-STAGE CLINICAL ONCOLOGY COMPANY DEVELOPING TARGETED THERAPIES FOR PATIENTS WITH RAS-ADDICTED CANCERS, TODAY ANNOUNCED THAT MARK A.

REVOLUTION MEDICINES TO PARTICIPATE IN NOVEMBER 2025 INVESTOR CONFERENCES

REDWOOD CITY, CALIF., OCT. 29, 2025 (GLOBE NEWSWIRE) -- REVOLUTION MEDICINES, INC. (NASDAQ: RVMD), A LATE-STAGE CLINICAL ONCOLOGY COMPANY DEVELOPING TARGETED THERAPIES FOR PATIENTS WITH RAS-ADDICTED CANCERS, TODAY ANNOUNCED THAT IT WILL REPORT FINANCIAL RESULTS FOR THE THIRD QUARTER OF 2025 ON WEDNESDAY, NOVEMBER 5, 2025, AFTER MARKET CLOSE. AT 4:30 P.M. ET THAT DAY (1:30 P.M. PT), MEMBERS OF REVOLUTION MEDICINES' SENIOR MANAGEMENT TEAM WILL HOST A WEBCAST TO DISCUSS THE FINANCIAL RESULTS FOR THE QUARTER AND PROVIDE AN UPDATE ON CORPORATE PROGRESS.

Revolution Medicines, Inc.

RVMD

Price

Financial Reports

No items found.

Press Releases

Revolution Medicines, Inc.

RVMD.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

RVMD